Form 4: Krystal Biotech Executive Suma Krishnan Reports Stock Transaction

Suma Krishnan, President of R&D at Krystal Biotech, reports the disposition of 2,353 shares for tax withholding purposes following the vesting of restricted stock.

Summary

• On February 26, 2024, Suma Krishnan, President of R&D at Krystal Biotech, surrendered 2,353 shares of common stock to the company for tax withholding.
• This was due to the vesting of 7,100 shares of restricted stock.
• The shares were surrendered at a price of $157, which was the closing price of Krystal Biotech's common stock on NASDAQ on that date.
• Following the transaction, Suma Krishnan directly owns 1,571,853 shares of common stock.
• She also has indirect ownership through her spouse (1,634,338 shares), the SMK Trust (90,000 shares), and the Krishnan Family Trust (50,000 shares).

Sentiment

Score: 5

Explanation: This is a neutral reporting of a routine stock transaction related to tax obligations. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their stock transactions. It's a standard practice for executives to surrender shares to cover tax obligations when restricted stock vests.

Key Dates